{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:43:24Z","timestamp":1790016204693,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s11064-021-03242-z","type":"journal-article","created":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T03:02:31Z","timestamp":1612148551000},"page":"732-739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Systematic Review of Erythropoietin (EPO) for Neuroprotection in Human Studies"],"prefix":"10.1007","volume":"46","author":[{"given":"Salman","family":"Hemani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0073-0604","authenticated-orcid":false,"given":"Olabisi","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-1861","authenticated-orcid":false,"given":"Sunil","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1335-1398","authenticated-orcid":false,"given":"Shan Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0644-6049","authenticated-orcid":false,"given":"Anna","family":"Woodbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"3242_CR1","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ki.1993.327","volume":"44","author":"PJ Ratcliffe","year":"1993","unstructured":"Ratcliffe PJ (1993) Molecular biology of erythropoietin. Kidney Int 44:887\u2013904. https:\/\/doi.org\/10.1038\/ki.1993.327","journal-title":"Kidney Int"},{"key":"3242_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S0889-8588(18)30134-5","volume":"8","author":"GL Semenza","year":"1994","unstructured":"Semenza GL (1994) Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. Hematol Oncol Clin North Am 8:863\u2013884","journal-title":"Hematol Oncol Clin North Am"},{"key":"3242_CR3","first-page":"640","volume":"89","author":"ED Zanjani","year":"1977","unstructured":"Zanjani ED, Poster J, Burlington H, Mann LI, Wasserman LR (1977) Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med 89:640\u2013644","journal-title":"J Lab Clin Med"},{"key":"3242_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2141.1996.d01-1864.x","volume":"95","author":"JW Fisher","year":"1996","unstructured":"Fisher JW, Koury S, Ducey T, Mendel S (1996) Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 95:27\u201332. https:\/\/doi.org\/10.1046\/j.1365-2141.1996.d01-1864.x","journal-title":"Br J Haematol"},{"key":"3242_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/153537020322800101","volume":"228","author":"JW Fisher","year":"2003","unstructured":"Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228:1\u201314. https:\/\/doi.org\/10.1177\/153537020322800101","journal-title":"Exp Biol Med (Maywood)"},{"key":"3242_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/BF03402029","volume":"8","author":"H Ehrenreich","year":"2002","unstructured":"Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M et al (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8:495\u2013505","journal-title":"Mol Med"},{"key":"3242_CR7","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.4103\/1673-5374.215240","volume":"12","author":"CC Hern\u00e1ndez","year":"2017","unstructured":"Hern\u00e1ndez CC, Burgos CF, Gajardo AH, Silva-Grecchi T, Gavilan J, Toledo JR et al (2017) Neuroprotective effects of erythropoietin on neurodegenerative and ischemic brain diseases: the role of erythropoietin receptor. Neural Regen Res 12:1381\u20131389. https:\/\/doi.org\/10.4103\/1673-5374.215240","journal-title":"Neural Regen Res"},{"key":"3242_CR8","doi-asserted-by":"publisher","first-page":"PMC6712762","DOI":"10.1177\/1759091419871420","volume":"11","author":"F Rey","year":"2019","unstructured":"Rey F, Balsari A, Giallongo T, Ottolenghi S, Di Giulio AM, Samaja M et al (2019) Erythropoietin as a neuroprotective molecule: an overview of its therapeutic potential in neurodegenerative diseases. ASN Neuro 11:PMC6712762. https:\/\/doi.org\/10.1177\/1759091419871420","journal-title":"ASN Neuro"},{"key":"3242_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1177\/1756285611434926","volume":"5","author":"N Subir\u00f3s","year":"2012","unstructured":"Subir\u00f3s N, del Barco DG, Coro-Antich RM (2012) Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 5:161\u2013173. https:\/\/doi.org\/10.1177\/1756285611434926","journal-title":"Ther Adv Neurol Disord"},{"key":"3242_CR10","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/sj.jcbfm.9600417","volume":"27","author":"Y Li","year":"2007","unstructured":"Li Y, Lu Z, Keogh CL, Yu SP, Wei L (2007) Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. J Cereb Blood Flow Metab 27:1043\u20131054. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600417","journal-title":"J Cereb Blood Flow Metab"},{"key":"3242_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1124\/jpet.105.094391","volume":"317","author":"L Wei","year":"2006","unstructured":"Wei L, Han BH, Li Y, Keogh CL, Holtzman DM, Yu SP (2006) Cell death mechanism and protective effect of erythropoietin after focal ischemia in the whisker-barrel cortex of neonatal rats. J Pharmacol Exp Ther 317:109\u2013116. https:\/\/doi.org\/10.1124\/jpet.105.094391","journal-title":"J Pharmacol Exp Ther"},{"key":"3242_CR12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1651-2227.2002.tb02904.x","volume":"91","author":"S Juul","year":"2002","unstructured":"Juul S (2002) Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 91:36\u201342","journal-title":"Acta Paediatr Suppl"},{"key":"3242_CR13","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood.V93.8.2627","volume":"93","author":"D Ribatti","year":"1999","unstructured":"Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell\u2019Era P et al (1999) Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93:2627\u20132636","journal-title":"Blood"},{"key":"3242_CR14","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1242\/jeb.01049","volume":"207","author":"HH Marti","year":"2004","unstructured":"Marti HH (2004) Erythropoietin and the hypoxic brain. J Exp Biol 207:3233\u20133242. https:\/\/doi.org\/10.1242\/jeb.01049","journal-title":"J Exp Biol"},{"key":"3242_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1469-7793.1999.0343v.x","volume":"516","author":"R Assandri","year":"1999","unstructured":"Assandri R, Egger M, Gassmann M, Niggli E, Bauer C, Forster I et al (1999) Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line. J Physiol 516:343\u2013352. https:\/\/doi.org\/10.1111\/j.1469-7793.1999.0343v.x","journal-title":"J Physiol"},{"key":"3242_CR16","doi-asserted-by":"publisher","first-page":"20465","DOI":"10.1074\/jbc.274.29.20465","volume":"274","author":"BA Miller","year":"1999","unstructured":"Miller BA, Barber DL, Bell LL, Beattie BK, Zhang MY, Neel BG et al (1999) Identification of the erythropoietin receptor domain required for calcium channel activation. J Biol Chem 274:20465\u201320472. https:\/\/doi.org\/10.1074\/jbc.274.29.20465","journal-title":"J Biol Chem"},{"key":"3242_CR17","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1073\/pnas.95.8.4635","volume":"95","author":"M Sakanaka","year":"1998","unstructured":"Sakanaka M, Wen T-C, Matsuda S, Masuda S, Morishita E, Nagao M et al (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. PNAS 95:4635\u20134640. https:\/\/doi.org\/10.1073\/pnas.95.8.4635","journal-title":"PNAS"},{"key":"3242_CR18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/00004647-199906000-00007","volume":"19","author":"M Bernaudin","year":"1999","unstructured":"Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET et al (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643\u2013651. https:\/\/doi.org\/10.1097\/00004647-199906000-00007","journal-title":"J Cereb Blood Flow Metab"},{"key":"3242_CR19","doi-asserted-by":"publisher","first-page":"10526","DOI":"10.1073\/pnas.97.19.10526","volume":"97","author":"ML Brines","year":"2000","unstructured":"Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C et al (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526\u201310531. https:\/\/doi.org\/10.1073\/pnas.97.19.10526","journal-title":"Proc Natl Acad Sci USA"},{"key":"3242_CR20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/glia.22851","volume":"63","author":"C-A Gr\u00e9goire","year":"2015","unstructured":"Gr\u00e9goire C-A, Goldenstein BL, Floriddia EM, Barnab\u00e9-Heider F, Fernandes KJL (2015) Endogenous neural stem cell responses to stroke and spinal cord injury. Glia 63:1469\u20131482. https:\/\/doi.org\/10.1002\/glia.22851","journal-title":"Glia"},{"key":"3242_CR21","doi-asserted-by":"publisher","first-page":"e28849","DOI":"10.5812\/aapm.28849","volume":"5","author":"A Nekoui","year":"2015","unstructured":"Nekoui A, Del Carmen Escalante Tresierra V, Abdolmohammadi S, Shedid D, Blaise G (2015) Neuroprotective effect of erythropoietin in postoperation cervical spinal cord injury: case report and review. Anesth Pain Med 5:e28849. https:\/\/doi.org\/10.5812\/aapm.28849","journal-title":"Anesth Pain Med"},{"key":"3242_CR22","doi-asserted-by":"publisher","first-page":"453179","DOI":"10.1155\/2011\/453179","volume":"2011","author":"S Carelli","year":"2011","unstructured":"Carelli S, Marfia G, Di Giulio AM, Ghilardi G, Gorio A (2011) Erythropoietin: recent developments in the treatment of spinal cord injury. Neurol Res Int 2011:453179. https:\/\/doi.org\/10.1155\/2011\/453179","journal-title":"Neurol Res Int"},{"key":"3242_CR23","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.expneurol.2007.12.020","volume":"210","author":"MH Theus","year":"2008","unstructured":"Theus MH, Wei L, Cui L, Francis K, Hu X, Keogh C et al (2008) In vitro hypoxic preconditioning of embryonic stem cells as a strategy of promoting cell survival and functional benefits after transplantation into the ischemic rat brain. Exp Neurol 210:656\u2013670. https:\/\/doi.org\/10.1016\/j.expneurol.2007.12.020","journal-title":"Exp Neurol"},{"key":"3242_CR24","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.nbd.2012.03.002","volume":"46","author":"L Wei","year":"2012","unstructured":"Wei L, Fraser JL, Lu Z-Y, Hu X, Yu SP (2012) Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. Neurobiol Dis 46:635\u2013645. https:\/\/doi.org\/10.1016\/j.nbd.2012.03.002","journal-title":"Neurobiol Dis"},{"key":"3242_CR25","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.nurt.2008.10.041","volume":"6","author":"A-L Sir\u00e9n","year":"2009","unstructured":"Sir\u00e9n A-L, Fa\u00dfhauer T, Bartels C, Ehrenreich H (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6:108\u2013127. https:\/\/doi.org\/10.1016\/j.nurt.2008.10.041","journal-title":"Neurotherapeutics"},{"issue":"1","key":"3242_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pathophys.2012.02.005","volume":"20","author":"LL Ponce","year":"2013","unstructured":"Ponce LL, Navarro JC, Ahmed O, Robertson CS (2013) Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology. 20(1):31\u201338","journal-title":"Pathophysiology."},{"issue":"42","key":"3242_CR27","doi-asserted-by":"publisher","first-page":"39469","DOI":"10.1074\/jbc.M105832200","volume":"276","author":"M Kawakami","year":"2001","unstructured":"Kawakami M, Sekiguchi M, Sato K, Kozaki S, Takahashi M (2001) Erythropoietin receptor-mediated inhibition of exocytotic glutamate release confers neuroprotection during chemical ischemia. J Biol Chem 276(42):39469\u201339475","journal-title":"J Biol Chem"},{"issue":"4","key":"3242_CR28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1203\/01.PDR.0000155760.88664.06","volume":"57","author":"A Sola","year":"2005","unstructured":"Sola A, Rogido M, Lee BH, Genetta T, Wen T-C (2005) Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr Res 57(4):481\u2013487","journal-title":"Pediatr Res"},{"issue":"5 Pt 2","key":"3242_CR29","doi-asserted-by":"publisher","first-page":"110R","DOI":"10.1203\/01.PDR.0000159571.50758.39","volume":"57","author":"A Sola","year":"2005","unstructured":"Sola A, Wen T-C, Hamrick SEG, Ferriero DM (2005) Potential for protection and repair following injury to the developing brain: a role for erythropoietin? Pediatr Res 57(5 Pt 2):110R\u2013117R","journal-title":"Pediatr Res"},{"issue":"14","key":"3242_CR30","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1096\/fj.05-3941fje","volume":"19","author":"E Kilic","year":"2005","unstructured":"Kilic E, Kilic U, Soliz J, Bassetti CL, Gassmann M, Hermann DM (2005) Brain-derived erythropoietin protects from focal cerebral ischemia by dual activation of ERK-1\/-2 and Akt pathways. FASEB J 19(14):2026\u20132028","journal-title":"FASEB J"},{"issue":"3","key":"3242_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.bbrc.2005.03.149","volume":"331","author":"C Culmsee","year":"2005","unstructured":"Culmsee C, Mattson MP (2005) P53 in neuronal apoptosis. Biochem Biophys Res Commun 331(3):761\u2013777","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"3242_CR32","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1101\/gad.13.22.2905","volume":"13","author":"SR Datta","year":"1999","unstructured":"Datta SR, Brunet A, Greenberg ME (1999) Cellular survival: a play in three Akts. Genes Dev 13(22):2905\u20132927","journal-title":"Genes Dev"},{"key":"3242_CR33","first-page":"S306","volume":"4","author":"B Asadi","year":"2013","unstructured":"Asadi B, Askari G, Khorvash F, Bagherpur A, Mehrabi F, Karimi M et al (2013) Neuroprotective effects of erythropoietin in acute ischemic stroke. Int J Prev Med 4:S306\u2013S312","journal-title":"Int J Prev Med"},{"key":"3242_CR34","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/sj.mp.4001907","volume":"12","author":"H Ehrenreich","year":"2007","unstructured":"Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S et al (2007) Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 12:206\u2013220. https:\/\/doi.org\/10.1038\/sj.mp.4001907","journal-title":"Mol Psychiatry"},{"key":"3242_CR35","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00213-010-1842-7","volume":"210","author":"K Miskowiak","year":"2010","unstructured":"Miskowiak K, Favaron E, Hafizi S, Inkster B, Goodwin G, Cowen P et al (2010) Erythropoietin modulates neural and cognitive processing of emotional information in biomarker models of antidepressant drug action in depressed patients. Psychopharmacology 210:419\u2013428. https:\/\/doi.org\/10.1007\/s00213-010-1842-7","journal-title":"Psychopharmacology"},{"key":"3242_CR36","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s10072-015-2182-5","volume":"36","author":"D Costa","year":"2015","unstructured":"Costa D, Beghi E, Carignano P, Pagliacci C, Faccioli F, Pupillo E et al (2015) Tolerability and efficacy of erythropoietin (EPO) treatment in traumatic spinal cord injury: a preliminary randomized comparative trial vs. methylprednisolone (MP). Neurol Sci 36:1567\u20131574. https:\/\/doi.org\/10.1007\/s10072-015-2182-5","journal-title":"Neurol Sci"},{"key":"3242_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ana.23573","volume":"72","author":"K S\u00fchs","year":"2012","unstructured":"S\u00fchs K, Hein K, S\u00e4ttler M, G\u00f6rlitz A, Ciupka C, Scholz K et al (2012) A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol 72:199\u2013210. https:\/\/doi.org\/10.1002\/ana.23573","journal-title":"Ann Neurol"},{"key":"3242_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s004020000197","volume":"121","author":"M Cemalettin Aksoy","year":"2001","unstructured":"Cemalettin Aksoy M, Mazhar TA (2001) Erythropoietin for autologous blood donation in total hip arthroplasty patients. Arch Orthop Trauma Surg 121:162\u2013165. https:\/\/doi.org\/10.1007\/s004020000197","journal-title":"Arch Orthop Trauma Surg"},{"key":"3242_CR39","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.arth.2005.12.002","volume":"21","author":"A Deutsch","year":"2006","unstructured":"Deutsch A, Spaulding J, Marcus RE (2006) Preoperative epoetin alfa vs autologous blood donation in primary total knee arthroplasty. J Arthroplast 21:628\u2013635. https:\/\/doi.org\/10.1016\/j.arth.2005.12.002","journal-title":"J Arthroplast"},{"key":"3242_CR40","doi-asserted-by":"publisher","first-page":"658","DOI":"10.2119\/molmed.2014.00215","volume":"20","author":"M Brines","year":"2015","unstructured":"Brines M, Dunne AN, van Velzen M, Proto PL, Ostenson C-G, Kirk RI et al (2015) ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med 20:658\u2013666. https:\/\/doi.org\/10.2119\/molmed.2014.00215","journal-title":"Mol Med"},{"key":"3242_CR41","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1744-8069-10-13","volume":"10","author":"M Swartjes","year":"2014","unstructured":"Swartjes M, van Velzen M, Niesters M, Aarts L, Brines M, Dunne A et al (2014) ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response. Mol Pain 10:13. https:\/\/doi.org\/10.1186\/1744-8069-10-13","journal-title":"Mol Pain"},{"key":"3242_CR42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.peptides.2016.01.003","volume":"76","author":"W Zhang","year":"2016","unstructured":"Zhang W, Yu G, Zhang M (2016) ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides 76:73\u201379. https:\/\/doi.org\/10.1016\/j.peptides.2016.01.003","journal-title":"Peptides"},{"key":"3242_CR43","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2119\/molmed.2012.00332","volume":"18","author":"L Heij","year":"2012","unstructured":"Heij L, Niesters M, Swartjes M, Hoitsma E, Drent M, Dunne A et al (2012) Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Mol Med 18:1430\u20131436. https:\/\/doi.org\/10.2119\/molmed.2012.00332","journal-title":"Mol Med"},{"key":"3242_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1517\/13543784.2014.892072","volume":"23","author":"M van Velzen","year":"2014","unstructured":"van Velzen M, Heij L, Niesters M, Cerami A, Dunne A, Dahan A, Brines M (2014) ARA 290 for treatment of small fiber neuropathy in sarcoidosis. Expert Opin Investig Drugs 23:541\u2013550","journal-title":"Expert Opin Investig Drugs"},{"key":"3242_CR45","doi-asserted-by":"publisher","first-page":"e647","DOI":"10.1161\/STROKEAHA.109.564872","volume":"40","author":"H Ehrenreich","year":"2009","unstructured":"Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K et al (2009) Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40:e647\u2013e656. https:\/\/doi.org\/10.1161\/STROKEAHA.109.564872","journal-title":"Stroke"},{"key":"3242_CR46","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/j.1600-6143.2012.04019.x","volume":"12","author":"Z Aydin","year":"2012","unstructured":"Aydin Z, Mallat MJK, Schaapherder AFM, van Zonneveld AJ, van Kooten C, Rabelink TJ et al (2012) Randomized trial of short-course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant 12:1793\u20131800. https:\/\/doi.org\/10.1111\/j.1600-6143.2012.04019.x","journal-title":"Am J Transplant"},{"key":"3242_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jacc.2016.04.040","volume":"68","author":"A Cariou","year":"2016","unstructured":"Cariou A, Deye N, Vivien B, Richard O, Pichon N, Bourg A et al (2016) Early high-dose erythropoietin therapy after out-of-hospital cardiac arrest: a multicenter, randomized controlled trial. J Am Coll Cardiol 68:40\u201349. https:\/\/doi.org\/10.1016\/j.jacc.2016.04.040","journal-title":"J Am Coll Cardiol"},{"key":"3242_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00264-011-1367-7","volume":"36","author":"M Buljan","year":"2012","unstructured":"Buljan M, Nemet D, Golubic-Cepulic B, Bicanic G, Tripkovic B, Delimar D (2012) Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty. Int Orthop (SICOT) 36:703\u2013709. https:\/\/doi.org\/10.1007\/s00264-011-1367-7","journal-title":"Int Orthop (SICOT)"},{"key":"3242_CR49","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jns.2013.11.015","volume":"337","author":"W Jang","year":"2014","unstructured":"Jang W, Park J, Shin K, Kim J, Kim J, Youn J et al (2014) Safety and efficacy of recombinant human erythropoietin treatment of non-motor symptoms in Parkinson\u2019s disease. J Neurol Sci 337:47\u201354. https:\/\/doi.org\/10.1016\/j.jns.2013.11.015","journal-title":"J Neurol Sci"},{"key":"3242_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3109\/17482960902995246","volume":"10","author":"G Lauria","year":"2009","unstructured":"Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L et al (2009) Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph Lateral Scler 10:410\u2013415. https:\/\/doi.org\/10.3109\/17482960902995246","journal-title":"Amyotroph Lateral Scler"},{"key":"3242_CR51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/1352458516661048","volume":"23","author":"K Schreiber","year":"2017","unstructured":"Schreiber K, Magyari M, Sellebjerg F, Iversen P, Garde E, Madsen C et al (2017) High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Mult Scler J 23:675\u2013685. https:\/\/doi.org\/10.1177\/1352458516661048","journal-title":"Mult Scler J"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-021-03242-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-021-03242-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T16:29:04Z","timestamp":1615393744000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-021-03242-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["3242"],"URL":"https:\/\/doi.org\/10.1007\/s11064-021-03242-z","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"15 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}